Abstract 496P
Background
Indication for treatment with osimertinib after first/second generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance depends on T790M mutation detected by re-biopsy. REMEDY trial consisting many cases using plasma biopsy revealed osimertinib introduction rate of approximately 25 percent in EGFR-mutant non-small cell lung cancer (NSCLC) patients pretreated with first/second generation EGFR-TKIs. The aim of study is to analyze the data on clinical practice of our hospital, where histological re-biopsy is actively carried out multiple times.
Methods
We retrospectively reviewed our electronic medical records of EGFR-mutant NSCLC patients to examine osimertinib introduction rate and associated outcomes.
Results
Among 95 patients with EGFR-mutant NSCLC, 73 patients received first/second generation EGFR-TKIs. Of 57 progressive disease patients, 50 patients (57/50: 87%) underwent re-biopsy. T790M was detected in 36 patients (36/50: 72%) and osimertinib was introduced in 35 patients (35/50: 70%). Among 36 patients harboring T790M mutation: histological re-biopsy was performed in 21 patients (21/36: 58%); cytology in 12 patients (12/36: 33%); blood biopsy in three patients (3/36: 8.3%). T790M was detected by first re-biopsy in 14 patients (14/36: 39%), and by second or subsequent re-biopsy 22 patients (22/36: 61%). The median overall survival (OS) in osimertinib induction patients was not reached (95% CI, 64.2-not reached) while in non- osimertinib patients median OS was 92.9 months (95% CI, 22.5-not reached) (p = 0.0173). Five year survival rates were 77% and 52%, respectively.
Conclusions
Higher osimertinib introduction rate was achieved by multiple repeated re-biopsy after first/second generation EGFR-TKIs, and its high introduction rate could contribute to better prognosis of EGFR-mutant NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kobe Minimally Invasive Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract